News | May 03, 2024
Novartis to acquire Mariana Oncology for upfront US$ 1 billion
Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications
Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications
Late-breaker Phase 3 STRIDE-10 trial presented as an oral presentation at European Society of Clinical Microbiology and Infectious Diseases
TIVDAK is the first antibody-drug conjugate (ADC) to have positive overall survival data for patients with previously treated recurrent or metastatic cervical cancer
Recommendation based on CAPItello-291 results which showed the Truqap combination reduced the risk of disease progression or death by 50%
If approved, the Opdivo-based regimen would be the first immunotherapy-chemotherapy combination approved for this patient population in the EU
Very strong revenue and EPS growth in the first quarter coupled with exciting pipeline delivery
Additional data in pregnant adults who are Virologically suppressed reinforce safety and tolerability profile of Biktarvy in broad range of people with HIV
Sales reflect continued strong growth in oncology and vaccines
Desidustat, administered orally is a novel, oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) for treating anaemia in Chronic Kidney Disease (CKD) patients
Open a printable version of this pageEmail the URL of this page to a friend
Subscribe To Our Newsletter & Stay Updated
